Li 2007.

Study characteristics
Methods	Aim: to investigate the efficacy and safety of paroxetine in the treatment of post‐stroke depression. Patients randomly divided into two groups
Participants	Stroke diagnosis: 4th Congress of Chinese Cerebrovascular Diseases, with brain CT or MRI to confirm the diagnosis. 30 cases of ischemic stroke and 14 cases of hemorrhagic stroke in the treatment group, and 31 cases of ischemic stroke and 11 cases of hemorrhagic stroke in the control group. Patients with prior depression, anxiety and schizophrenia were excluded HAMD Score ≥ 18
Interventions	Both groups were given usual medical care, the treatment group was give paroxetine tablets (Zhejiang Huahai Pharmaceutical Co., Ltd.,), 20mg, once per day orally in the morning for 8 weeks; the control group was given the placebo, dose not reported, once per day orally in the morning for 8 weeks
Outcomes	Depression score at treatment of 2‐week, 4‐week and 8‐week Neurological deficiency score at treatment of 2‐week, 4‐week and 8‐week
Funding source	Unclear
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information provided
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information provided
Selective reporting (reporting bias)	Unclear risk	No information provided
Other bias	Unclear risk	No information provided